Neurocrine Lands FDA Nod for First New Treatment in Decades for Rare Endocrine Disorder

Neurocrine Biosciences’ Crenessity is now FDA approved for treating classic congenital adrenal hyperplasia (CAH), a rare and potentially fatal endocrine disorder. The approval comes with a priority review voucher, which Neurocrine could sell for around $150 million. The post Neurocrine Lands FDA Nod for First New Treatment in Decades for Rare Endocrine Disorder appeared first…

New investigation rips Amazon’s safety record. That’s not slowing the tech giant’s stock.

Injuries at Amazon.com Inc.’s warehouses are more common than in other warehouses, a new government report alleged over the weekend, claiming that the online-retail giant manipulated injury data and ignored recommendations to keep workers safer as it pursued speed and profits.

NYC comedy club cancels show after anti-Israel backlash over event meant to heal division in wake of Oct. 7 terror attacks 

The event, dubbed “Debate, Don’t Hate,” at Stand Up NY in Manhattan was designed to use the power of comedy to foster an open dialogue about the ongoing war between Israel and Hamas in the Gaza Strip.

Daily Digest: Embedding nature in underwriting, AIG launches reinsurance syndicate, California catastrophe modelling rules take effect

Catch up on the essential news and analysis from the Insurance Day experts       Related Stories Lockton launches global parametric insurance practice Axis strikes $2.3bn legacy deal with Enstar Rule takes effect for California insurers to use catastrophe modelling in rate-setting